Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 76


TP53-Associated Pediatric Malignancies.

Pinto EM, Ribeiro RC, Figueiredo BC, Zambetti GP.

Genes Cancer. 2011 Apr;2(4):485-90. doi: 10.1177/1947601911409745.


High frequency of germline p53 mutations in childhood adrenocortical cancer.

Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D.

J Natl Cancer Inst. 1994 Nov 16;86(22):1707-10.


Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors.

Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DG, Harris M, Kelsey AM, Birch JM.

Am J Hum Genet. 1999 Oct;65(4):995-1006.


Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.

Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C, Bertherat J.

Clin Cancer Res. 2007 Feb 1;13(3):844-50.


Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.

Tworek H, Peng R, Fetzer S, Werness BA, Piver MS, Allen HJ, DiCioccio RA.

Cancer Genet Cytogenet. 1999 Jul 15;112(2):105-18.


Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor.

Pinto EM, Ribeiro RC, Kletter GB, Lawrence JP, Jenkins JJ, Wang J, Shurtleff S, McGregor L, Kriwacki RW, Zambetti GP.

Fam Cancer. 2011 Mar;10(1):141-6. doi: 10.1007/s10689-010-9392-z.


Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH.

Breast Cancer Res. 2012 Apr 16;14(2):R66.


p53 from basic research to clinical applications.

Tominaga O, Hamelin R, Remvikos Y, Salmon RJ, Thomas G.

Crit Rev Oncog. 1992;3(3):257-82. Review.


Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.

Giacomazzi J, Selistre SG, Rossi C, Alemar B, Santos-Silva P, Pereira FS, Netto CB, Cossio SL, Roth DE, Brunetto AL, Zagonel-Oliveira M, Martel-Planche G, Goldim JR, Hainaut P, Camey SA, Ashton-Prolla P.

Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7.


Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M.

Hum Mutat. 2007 Jun;28(6):622-9.


A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer.

Cho Y, Kim J, Kim Y, Jeong J, Lee KA.

Ann Lab Med. 2013 May;33(3):212-6. doi: 10.3343/alm.2013.33.3.212. Epub 2013 Apr 17.


Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation.

Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC.

J Med Genet. 2006 Jan;43(1):91-6. Epub 2005 Jul 20.


Childhood adrenocortical carcinoma as a sentinel cancer for detecting families with germline TP53 mutations.

Choong SS, Latiff ZA, Mohamed M, Lim LL, Chen KS, Vengidasan L, Razali H, Abdul Rahman EJ, Ariffin H; Malaysian Society of Paediatric Haematology-Oncology.

Clin Genet. 2012 Dec;82(6):564-8. doi: 10.1111/j.1399-0004.2012.01841.x. Epub 2012 Jan 30.


TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M.

Oncogene. 2007 Apr 2;26(15):2157-65. Review.


Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma.

Russell-Swetek A, West AN, Mintern JE, Jenkins J, Rodriguez-Galindo C, Ribeiro R, Zambetti GP.

J Med Genet. 2008 Sep;45(9):603-6. doi: 10.1136/jmg.2008.059568.


Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IeM, Kurman RJ.

Mod Pathol. 2011 Sep;24(9):1248-53. doi: 10.1038/modpathol.2011.85. Epub 2011 May 6.


A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors.

Trkova M, Foretova L, Kodet R, Hedvicakova P, Sedlacek Z.

Cancer Genet Cytogenet. 2003 Aug;145(1):60-4.


Contribution of p53, p63, and p73 to the developmental diseases and cancer.

Tomkova K, Tomka M, Zajac V.

Neoplasma. 2008;55(3):177-81. Review.


p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.


High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.

Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk